DATE: December 14, 2017
TIME: 08:00am PST, 11:00am EST, 4:00pm BST, 5:00pm CEST
The benefits of genomic analysis are well understood, however, the majority of patients do not harbor druggable alterations in their genomes and thus are not candidates for targeted therapies. In patients whose tumors lack genomic biomarkers for targeted therapies or have developed resistance, clinical proteomics is identifying protein biomarkers for therapies that are benefitting patients—thus fueling the emergence of proteogenomics.
We have built more than 250 quantitative proteomic assays for relevant oncology biomarkers expressed in solubilized, formalin-fixed, paraffin-embedded tumor samples using selected reaction monitoring mass spectrometry. This webinar will cover the assay development pipeline utilized to bring these quantitative proteomic markers into our CAP-CLIA laboratory. Starting from a targeted-discovery initiative to the analytical validation of our multiplexed SRM methods, we will discuss the metrics used to validate our assays.
Additionally, this webinar will introduce the impact these developed markers have on clinical research, including the retrospective analyses of HER2 proteomic expression in adjuvant and metastatic breast cancer and in advanced gastric cancer. The HER2 proteomic expression levels correlated with response to trastuzumab. From this correlation, we were able to identify a proteomic cut-off value of response. This potential benefit extended to donors identified as non-breast/non-gastric cancer patients who overexpressed HER2 and who subsequently responded to HER2-targeted therapy.
Key Learning Objectives:
WAVE Newsletter Promotion1%
Medical Laboratory Technician8%
Clinical Laboratory Scientist6%
Life Science Company3%
Medical Device Company2%